Exagen (XGN) Stock Overview
Designs, develops, and commercializes various testing products under the AVISE brand in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
XGN Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Exagen Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.47 |
| 52 Week High | US$12.23 |
| 52 Week Low | US$2.59 |
| Beta | 1.81 |
| 1 Month Change | 14.14% |
| 3 Month Change | 5.79% |
| 1 Year Change | -39.55% |
| 3 Year Change | 10.16% |
| 5 Year Change | -73.29% |
| Change since IPO | -81.32% |
Recent News & Updates
Analysis Article • 19m
Exagen Inc. (NASDAQ:XGN) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
Exagen Inc. ( NASDAQ:XGN ) just released its first-quarter report and things are looking bullish. Revenues and losses...
Narrative Update • Apr 24
XGN: Volume Strength And 2026 Guidance Should Support Future Share Gains
Narrative Update on Exagen Analysts have trimmed the average price target on Exagen by about $0.83 to reflect updated assumptions for slower revenue growth, softer profit margins, and more modest ASP and gross margin expansion in their models. Analyst Commentary Recent research shows analysts aligning around a more conservative view on Exagen, with several price targets reset to a tighter range as models are updated for softer pricing and margin assumptions.Narrative Update • Apr 10
XGN: Shares Should Rise As Volumes Offset Transitory Pricing Headwinds
Analysts have reduced their average 12 month price target on Exagen by a few dollars to around $9.50, citing lower than expected average selling prices as well as more conservative revenue and margin assumptions across recent research updates. Analyst Commentary Recent research updates point to a more cautious stance on Exagen, with several firms trimming their price targets while maintaining generally positive ratings on the shares.Recent updates
Analysis Article • 19m
Exagen Inc. (NASDAQ:XGN) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
Exagen Inc. ( NASDAQ:XGN ) just released its first-quarter report and things are looking bullish. Revenues and losses...Narrative Update • Apr 24
XGN: Volume Strength And 2026 Guidance Should Support Future Share Gains
Narrative Update on Exagen Analysts have trimmed the average price target on Exagen by about $0.83 to reflect updated assumptions for slower revenue growth, softer profit margins, and more modest ASP and gross margin expansion in their models. Analyst Commentary Recent research shows analysts aligning around a more conservative view on Exagen, with several price targets reset to a tighter range as models are updated for softer pricing and margin assumptions.Narrative Update • Apr 10
XGN: Shares Should Rise As Volumes Offset Transitory Pricing Headwinds
Analysts have reduced their average 12 month price target on Exagen by a few dollars to around $9.50, citing lower than expected average selling prices as well as more conservative revenue and margin assumptions across recent research updates. Analyst Commentary Recent research updates point to a more cautious stance on Exagen, with several firms trimming their price targets while maintaining generally positive ratings on the shares.Narrative Update • Mar 26
XGN: Shares Should Rise As Volumes Support Long Term Margin Recovery
Analysts have reset expectations on Exagen, with several firms trimming their price targets to around $9 to $10. They cite lower than anticipated average selling prices, tempered revenue growth assumptions, and more gradual gross margin expansion in their updated models.Narrative Update • Mar 12
XGN: Shares Should Rise As Solid Volumes Offset Near Term Pricing Headwinds
The analyst price target for Exagen has been revised from a fair value of $13.29 to $9.50. Analysts have updated their models to account for lower near-term average selling prices, more conservative revenue growth assumptions, and more modest margin expectations, although overall volume trends remain generally stable.Narrative Update • Feb 11
XGN: Shares Will Rise As 2025 Revenue Guidance Supports Bullish Outlook
Narrative Update on Exagen The updated analyst price target for Exagen has moved lower to about $13.29 from $14.71. This reflects analysts' recent cuts to formal targets in the diagnostics group and slightly more conservative assumptions on fair value, discount rate, revenue growth, profit margin and future P/E.Narrative Update • Jan 27
XGN: Shares Will Rise As 2025 Guidance And Sector Fundamentals Strengthen Outlook
Analysts trimmed their price target on Exagen to $13 from $18, citing updated sector views from recent Q4 previews, even as they continue to expect solid diagnostics group fundamentals and 2026 outlooks. Analyst Commentary Bullish Takeaways Bullish analysts view the updated US$13 price target as still supported by what they describe as solid fundamentals across the diagnostics group, which they see as relevant for Exagen's valuation framework.Analysis Article • Jan 14
Investors Don't See Light At End Of Exagen Inc.'s (NASDAQ:XGN) Tunnel And Push Stock Down 28%
Unfortunately for some shareholders, the Exagen Inc. ( NASDAQ:XGN ) share price has dived 28% in the last thirty days...Narrative Update • Jan 12
XGN: Shares Will Rise As 2025 Guidance Supports Profitability Milestone
The updated analyst price target for Exagen reflects a move to roughly $14.71 from about $15.43, as analysts weigh mixed signals from recent target changes and sector commentary around solid diagnostics fundamentals, alongside ongoing headwinds in life science tools. Analyst Commentary Recent research on Exagen points to a mixed but constructive view, with price targets adjusted both higher and lower as analysts rework their models around upcoming earnings and sector trends.Narrative Update • Dec 21
XGN: Shares Will Rise As Resilient Demand Supports 2025 Profitability Prospects
Analysts raised their price target on Exagen to $15.00 from $11.00, citing updated models ahead of Q3 results that account for resilient fundamentals despite ongoing headwinds in life science tools, including tariffs, funding uncertainty, and China related pressures. Analyst Commentary Bullish analysts view the higher price target as a reflection of Exagen's ability to execute against a difficult macro backdrop and to sustain growth despite sector wide pressures.Analysis Article • Dec 18
Is Exagen (NASDAQ:XGN) Using Debt Sensibly?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Narrative Update • Dec 07
XGN: Shares Will Rise As Autoimmune Test Adoption Drives 50% Upside Potential
Analysts have lifted their price target on Exagen to $15 from $11, citing a refreshed model that reflects confidence in the company’s autoimmune diagnostics platform and its flagship AVISE CTD test, despite ongoing macro headwinds in the life science tools sector. Analyst Commentary Bullish analysts point to Exagen’s specialized focus on autoimmune diagnostics and its AVISE CTD test as key drivers of potential upside, supporting the higher price target and Buy rating in spite of sector-wide pressures.Narrative Update • Nov 22
XGN: Shares Will Gain As Buy Ratings Signal 50% Upside Potential
Analysts have raised their price target for Exagen from $14.00 to $15.43. They cite improved revenue growth estimates and ongoing optimism for the company's diagnostic test portfolio, despite sector headwinds.Analysis Article • Nov 18
The Market Doesn't Like What It Sees From Exagen Inc.'s (NASDAQ:XGN) Revenues Yet As Shares Tumble 27%
Exagen Inc. ( NASDAQ:XGN ) shareholders won't be pleased to see that the share price has had a very rough month...Analysis Article • Nov 07
Earnings Update: Here's Why Analysts Just Lifted Their Exagen Inc. (NASDAQ:XGN) Price Target To US$14.43
It's been a sad week for Exagen Inc. ( NASDAQ:XGN ), who've watched their investment drop 12% to US$10.38 in the week...Narrative Update • Nov 06
XGN: Shares Set To Climb On Strong Buy Ratings And 50% Upside Potential
Analysts have raised their price target for Exagen, increasing it from approximately $13.14 to $14.00 per share. They cite improved profit margin forecasts and confidence in the company’s diagnostic offerings, despite ongoing sector challenges.Narrative Update • Oct 23
Analysts Boost Exagen Price Target Highlighting Growth Potential and Strong Diagnostic Portfolio
Analysts have raised their price target for Exagen from approximately $11.17 to $13.14. They cite confidence in the company’s diagnostic test portfolio and expectations for improved adoption and financial performance.Seeking Alpha • Sep 13
Exagen's Momentum Meets Execution Risks: Why I Choose To HOLD For Now
Summary Exagen Inc. has rebounded to 52-week highs, driven by record Q2 revenue, higher ASP, and a strengthened balance sheet. XGN's pipeline, including PAD4 and lupus nephritis diagnostics, presents significant long-term growth opportunities but faces regulatory and reimbursement risks. Recent payer wins and executive appointments enhance commercial prospects, but collections risk and delayed insurance payments threaten near-term revenue stability. Given execution risks and valuation premium, I rate XGN as HOLD, awaiting clearer visibility on collections, payer wins, and PAD4 approval. Read the full article on Seeking AlphaAnalysis Article • Aug 05
Exagen Inc.'s (NASDAQ:XGN) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
NasdaqGM:XGN 1 Year Share Price vs Fair Value Explore Exagen's Fair Values from the Community and select yours Despite...Analysis Article • Aug 01
Exagen Inc. (NASDAQ:XGN) Analysts Are Pretty Bullish On The Stock After Recent Results
It's been a pretty great week for Exagen Inc. ( NASDAQ:XGN ) shareholders, with its shares surging 16% to US$8.40 in...Analysis Article • May 18
Exagen Inc.'s (NASDAQ:XGN) Shares Bounce 34% But Its Business Still Trails The Industry
Exagen Inc. ( NASDAQ:XGN ) shares have continued their recent momentum with a 34% gain in the last month alone. The...Analysis Article • May 09
Earnings Update: Here's Why Analysts Just Lifted Their Exagen Inc. (NASDAQ:XGN) Price Target To US$7.75
As you might know, Exagen Inc. ( NASDAQ:XGN ) recently reported its quarterly numbers. It looks like a positive result...Seeking Alpha • Apr 26
Exagen: Buy An Undervalued Diagnostics Developer That Is On The Path To Profitability
Summary We initiate coverage on Exagen with a Buy rating, citing a promising turnaround with growing diagnostics, improved margins, and new biomarker tests for lupus and RA. Despite a rocky history, Exagen's recent momentum, modest valuation, and potential upside from new products make it an attractive long-term speculative buy. Financially, Exagen reported $55.6 million in 2024 revenue, improved margins, and expects positive adjusted EBITDA by Q4 2025, supported by new product launches. Key risks include reimbursement uncertainty, competition, cash burn, and execution challenges, but these are balanced by the stock's current valuation and growth potential. Read the full article on Seeking Alpha
New Narrative • Apr 09
Biomarker Launch And AVISE CTD Expansion Will Drive Future Success
New biomarkers and biopharma partnerships are expected to drive revenue growth and enhance diagnostic capabilities, accelerating earnings growth.Analysis Article • Apr 03
There's No Escaping Exagen Inc.'s (NASDAQ:XGN) Muted Revenues Despite A 45% Share Price Rise
The Exagen Inc. ( NASDAQ:XGN ) share price has done very well over the last month, posting an excellent gain of 45...Analysis Article • Mar 04
Is Exagen (NASDAQ:XGN) Using Debt In A Risky Way?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analysis Article • Feb 05
Exagen Inc. (NASDAQ:XGN) Surges 40% Yet Its Low P/S Is No Reason For Excitement
Exagen Inc. ( NASDAQ:XGN ) shares have continued their recent momentum with a 40% gain in the last month alone. The...Analysis Article • Dec 22
Exagen Inc.'s (NASDAQ:XGN) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
Despite an already strong run, Exagen Inc. ( NASDAQ:XGN ) shares have been powering on, with a gain of 26% in the last...Analysis Article • Sep 06
Improved Revenues Required Before Exagen Inc. (NASDAQ:XGN) Stock's 40% Jump Looks Justified
Despite an already strong run, Exagen Inc. ( NASDAQ:XGN ) shares have been powering on, with a gain of 40% in the last...Analysis Article • Aug 07
Analyst Estimates: Here's What Brokers Think Of Exagen Inc. (NASDAQ:XGN) After Its Second-Quarter Report
Exagen Inc. ( NASDAQ:XGN ) just released its quarterly report and things are looking bullish. The results overall were...Analysis Article • Jul 13
Insufficient Growth At Exagen Inc. (NASDAQ:XGN) Hampers Share Price
You may think that with a price-to-sales (or "P/S") ratio of 0.6x Exagen Inc. ( NASDAQ:XGN ) is definitely a stock...Analysis Article • May 21
Is Exagen (NASDAQ:XGN) Using Debt In A Risky Way?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analysis Article • Mar 26
Why Investors Shouldn't Be Surprised By Exagen Inc.'s (NASDAQ:XGN) 31% Share Price Plunge
Exagen Inc. ( NASDAQ:XGN ) shareholders won't be pleased to see that the share price has had a very rough month...Analysis Article • Mar 22
Analysts Have Made A Financial Statement On Exagen Inc.'s (NASDAQ:XGN) Annual Report
Exagen Inc. ( NASDAQ:XGN ) just released its latest yearly results and things are looking bullish. Exagen beat...Analysis Article • Jul 21
Exagen Inc.'s (NASDAQ:XGN) Business And Shares Still Trailing The Industry
With a price-to-sales (or "P/S") ratio of 0.9x Exagen Inc. ( NASDAQ:XGN ) may be sending very bullish signals at the...Seeking Alpha • Oct 17
Exagen appoints John Aballi as CEO
Exagen (NASDAQ:XGN) has appointed John Aballi as CEO and President. Longtime CEO and President Ron Rocca, who took the company public and built a robust growth business, is stepping down after 11 years at the helm. Most recently, John Aballi served as SVP, General Manager, Urology & CLIA COO at Veracyte.Analysis Article • Aug 10
Analysts Just Slashed Their Exagen Inc. (NASDAQ:XGN) EPS Numbers
Market forces rained on the parade of Exagen Inc. ( NASDAQ:XGN ) shareholders today, when the analysts downgraded their...Analysis Article • Jul 26
Exagen (NASDAQ:XGN) Has Debt But No Earnings; Should You Worry?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analysis Article • Apr 05
Is Exagen (NASDAQ:XGN) Weighed On By Its Debt Load?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analysis Article • Dec 03
Does Exagen (NASDAQ:XGN) Have A Healthy Balance Sheet?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Shareholder Returns
| XGN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 18.0% | -0.5% | 0.5% |
| 1Y | -39.5% | 44.4% | 25.4% |
Return vs Industry: XGN underperformed the US Biotechs industry which returned 44.4% over the past year.
Return vs Market: XGN underperformed the US Market which returned 25.4% over the past year.
Price Volatility
| XGN volatility | |
|---|---|
| XGN Average Weekly Movement | 13.3% |
| Biotechs Industry Average Movement | 10.6% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.0% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: XGN's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: XGN's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 218 | John Aballi | www.exagen.com |
Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company’s lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms.
Exagen Inc. Fundamentals Summary
| XGN fundamental statistics | |
|---|---|
| Market cap | US$83.77m |
| Earnings (TTM) | -US$20.17m |
| Revenue (TTM) | US$68.38m |
1.2x
P/S Ratio-4.2x
P/E RatioIs XGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XGN income statement (TTM) | |
|---|---|
| Revenue | US$68.38m |
| Cost of Revenue | US$28.50m |
| Gross Profit | US$39.88m |
| Other Expenses | US$60.05m |
| Earnings | -US$20.17m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.84 |
| Gross Margin | 58.32% |
| Net Profit Margin | -29.49% |
| Debt/Equity Ratio | 158.5% |
How did XGN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/14 11:48 |
| End of Day Share Price | 2026/05/13 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Exagen Inc. is covered by 7 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Anderson Schock | B. Riley Securities, Inc. |
| Mark Massaro | BTIG |
| Kyle Mikson | Canaccord Genuity |